Potential application of the D-amino acid oxidase (DAAO) inhibitor sodium benzoate for individuals experiencing psychological stress after traumatic events

Shih-Hsien Lin, Muhammad Abdullah, Li-Chung Huang, Yen Kuang Yang

Abstract


Preventing post-traumatic stress disorder (PTSD), which is harmful in terms of human resources and burdens society, is an urgent issue. The glutamatergic system, a newly-identified target site of recent pharmacological interventions for various mental disorders, could be a potential pathway. A recent study confirmed that sodium benzoate, which is a D-amino acid oxidase (DAAO) inhibitor that is used as a safe food additive, is therapeutically effective for certain mental disorders. Studies also indicated a medium effect size on the perceived stress and 28%-61% reduction of panic symptoms. Hereby, we propose a novel clinically oriented medical idea: “proper use of sodium benzoate in the preparation of rations for individuals with mental disorders who will be or are currently exposed to stressors could be a feasible method for preventing PTSD and other associated mental disorders”. While this idea remains to be tested, its application could be helpful for rescue workers or victims of disaster.

Keywords: Amino Acid Oxidase (DAAO) Inhibitor; Glutamate; Immune Response; Post-Traumatic Stress Disorder (PTSD); Ration; Sodium Benzoate


Full Text:

PDF

References


Lindley SE, Carlson EB, Hill KR. Psychotic-like experiences, symptom expression, and cognitive performance in combat veterans with posttraumatic stress disorder. Journal of Nervous and Mental Disease, (2014); 202(2): 91-96.

Bryant RA. The current evidence for acute stress disorder. Current Psychiatry Reports, (2018); 20(12): 111.

Hruby A, Lieberman HR, Smith TJ. Symptoms of depression, anxiety, and post-traumatic stress disorder and their relationship to health-related behaviors in over 12,000 US military personnel: Bi-directional associations. Journal of Affective Disorders, (2021); 28384-93.

Bryant RA. Post-traumatic stress disorder: a state-of-the-art review of evidence and challenges. World Psychiatry, (2019); 18(3): 259-269.

Davis LL, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, et al. The economic burden of posttraumatic stress disorder in the United States from a societal perspective. Journal of Clinical Psychiatry, (2022); 83(3): 21m14116.

Sijbrandij M, Kleiboer A, Bisson JI, Barbui C, Cuijpers P. Pharmacological prevention of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis. The Lancet Psychiatry, (2015); 2(5): 413-421.

Astill Wright L, Sijbrandij M, Sinnerton R, Lewis C, Roberts NP, et al. Pharmacological prevention and early treatment of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis. Translational Psychiatry, (2019); 9(1): 334.

Sultana E, Shastry N, Kasarla R, Hardy J, Collado F, et al. Disentangling the effects of PTSD from Gulf War Illness in male veterans via a systems-wide analysis of immune cell, cytokine, and symptom measures. Military Medical Research, (2024); 11(1): 2.

Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, et al. Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. Neuroscience Letters, (2017); 649147-155.

Nair J, Singh Ajit S. The role of the glutamatergic system in posttraumatic stress disorder. CNS Spectrums, (2008); 13(7): 585-591.

Averill LA, Jiang L, Purohit P, Coppoli A, Averill CL, et al. Prefrontal glutamate neurotransmission in PTSD: a novel approach to estimate synaptic strength in vivo in humans. Chronic Stress, (2022); 6: 24705470221092734.

Kim J, Kim TE, Lee SH, Koo JW. The role of glutamate underlying treatment-resistant depression. Clinical Psychopharmacology and Neuroscience, (2023); 21(3): 429-446.

Iwata Y, Nakajima S, Suzuki T, Keefe RSE, Plitman E, et al. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Molecular Psychiatry, (2015); 20(10): 1151-1160.

Walczak-Nowicka LJ, Herbet M. Sodium benzoate-harmfulness and potential use in therapies for disorders related to the nervous system: a review. Nutrients, (2022); 14(7): 1497.

Lin CH, Lin CH, Chang YC, Huang YJ, Chen PW, et al. Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Biological Psychiatry, (2018); 84(6): 422-432.

Wolosker H, Balu DT. d-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders. Translational Psychiatry, (2020); 10(1): 184.

Lee C-W, Fang Y-P, Chu M-C, Chung Y-J, Chi H, et al. Differential mechanisms of synaptic plasticity for susceptibility and resilience to chronic social defeat stress in male mice. Biochemical and Biophysical Research Communications, (2021); 562112-118.

Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, et al. Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. Neuroscience Letters, (2017); 649147-155.

Scott JG, Baker A, Lim CCW, Foley S, Dark F, et al. Effect of sodium benzoate vs placebo among individuals with early psychosis: a randomized clinical trial. JAMA Netw Open, (2020); 3(11): e2024335.

Brahmachari S, Pahan K. Sodium benzoate, a food additive and a metabolite of cinnamon, modifies T cells at multiple steps and inhibits adoptive transfer of experimental allergic encephalomyelitis. Journal of Immunology, (2007); 179(1): 275-283.

Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry, (2013); 70(12): 1267-1275.

Lin CH, Wang SH, Lane HY. Effects of sodium benzoate, a D-amino acid oxidase inhibitor, on perceived stress and cognitive function among patients with late-life depression: a randomized, double-blind, sertraline- and placebo-controlled trial. International Journal of Neuropsychopharmacology, (2022); 25(7): 545-555.

Hou YC, Lai CH. A kind of D-amino acid oxidase inhibitor, sodium benzoate, might relieve panic symptoms in a first-episode, drug-naïve panic-disorder patient. Journal of Neuropsychiatry and Clinical Neurosciences, (2013); 25(2): E7-8.

Zohar J, Fostick L, Juven-Wetzler A, Kaplan Z, Shalev H, et al. Secondary prevention of chronic PTSD by early and short-term administration of escitalopram: a prospective randomized, placebo-controlled, double-blind trial. Journal of Clinical Psychiatry, (2018); 79(2): 16m10730.

Richter-Levin G, Stork O, Schmidt MV. Animal models of PTSD: a challenge to be met. Molecular Psychiatry, (2019); 24(8): 1135-1156.

Dong C, Zhang JC, Ren Q, Ma M, Qu Y, et al. Deletion of serine racemase confers D-serine -dependent resilience to chronic social defeat stress. Neurochemistry International, (2018); 11643-51.

Burket JA, Pickle JC, Rusk AM, Haynes BA, Sharp JA, et al. Glycine transporter type 1 (GlyT1) inhibition improves conspecific-provoked immobility in BALB/c mice: Analysis of corticosterone response and glucocorticoid gene expression in cortex and hippocampus. Progress in Neuro-Psychopharmacology and Biological Psychiatry, (2020); 99: 109869.




DOI: http://dx.doi.org/10.62940/als.v12i1.3310

Refbacks

  • There are currently no refbacks.